Harvard Bioscience, Inc. (HBIO)

Market Cap	20.03M
Revenue (ttm)	91.40M
Net Income (ttm)	-58.05M
Shares Out	44.21M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	12.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,679
Open	0.4698
Previous Close	0.4695
Day's Range	0.4322 - 0.4750
52-Week Range	0.2813 - 3.6000
Beta	1.53
Analysts	Buy
Price Target	3.00 (+562.25%)
Earnings Date	Aug 7, 2025

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems f...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 7, 2000
• Employees: 355
• Stock Exchange: NASDAQ
• Ticker Symbol: HBIO
• Website: https://www.harvardbioscience.com

Financial Performance

In 2024, Harvard Bioscience's revenue was $94.14 million, a decrease of -16.14% compared to the previous year's $112.25 million. Losses were -$12.41 million, 263.3% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 562.25% from the latest price.

Price Target

$3.0

(562.25% upside)

Analyst Consensus: Buy